Séverine Péchiné

Dr. Séverine Péchiné


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2007 in Vaccine
Verified
Journal Article
Closed access
SPSéverine Péchiné
Séverine Péchiné
CJClaire Janoir
Claire Janoir
HBHélène Boureau
Hélène Boureau
AGAude Gleizes
Aude Gleizes
NTNicolas Tsapis
Nicolas Tsapis
ACAnne Collignon
Anne Collignon

1 October 2011 in FEMS Immunology & Medical Microbiology
Verified
Journal Article
Open access
PDF file
SPSéverine Péchiné
Séverine Péchiné
CDCécile Denève
Cécile Denève
AMAlban Le Monnier
Alban Le Monnier
SHSandra Hoys
Sandra Hoys
CJClaire Janoir
Claire Janoir
ACAnne Collignon
Anne Collignon
Clostridium difficile is a pathogen responsible for diarrhoea and colitis, particularly after antibiotic treatment. We evaluated the C. difficile pro

1 February 2016 in Anaerobe
Verified
Journal Article
Closed access
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
AMA. Mizrahi
A. Mizrahi
SHS. Hoys
S. Hoys
ACA. Collignon
A. Collignon
CJC. Janoir
C. Janoir
SPSéverine Péchiné
Séverine Péchiné

26 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SPSéverine Péchiné
Séverine Péchiné
CHClaire Hennequin
Claire Hennequin
CBCéline Boursier
Céline Boursier
SHSandra Hoys
Sandra Hoys
ACAnne Collignon
Anne Collignon
Clostridium difficile is a pathogen which is responsible for diarrhea and colitis, particularly after treatment with antibiotics. Clinical signs are mainly due to two toxins, TcdA and TcdB. However, the first step of pathogenesis is the colonization process. We evaluated C. difficile surface proteins as vaccine antigens in the hamster model to prevent intestinal colonization. This vaccination induced a partial protection of hamsters against death after a C. difficile challenge. A proteomic analysis of animal sera allowed us to identify proteins which could be responsible for the protection observed. Among these proteins, we identified the GroEL heat shock protein. To confirm the role of the specific GroEL antibodies in the delayed C. difficile colonization of hamsters, we performed an immunization assay in a mouse model. After intranasal immunization with the recombinant protein GroEL, we observed a lower C. difficile intestinal colonization in the immunized group as compared to the control group.

27 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Jean-François BruxelleJean-François Bruxelle
Jean-François Bruxelle
AMAssaf Mizrahi
Assaf Mizrahi
SHSandra Hoÿs
Sandra Hoÿs
ACAnne Collignon
Anne Collignon
CJClaire Janoir
Claire Janoir
SPSéverine Péchiné
Séverine Péchiné
The immunogenicity of bacterial flagellin has been reported in different studies. By its close interaction with the immune system, the flagellin represents an interesting adjuvant and vaccine candidate. Salmonella Typhimurium flagellin has already been tested as adjuvant to stimulate mucosal immunity. Here, we assessed the ability of Clostridium difficile flagellin FliC to act as a mucosal adjuvant, first combined with ovalbumin as antigen and second with a C. difficile surface protein, the precursor of the S-layer proteins SlpA. Using ovalbumin as antigen, we compared the gut mucosal adjuvanticity of FliC to Salmonella Typhimurium flagellin and cholera toxin. Two routes of immunization were tested in a mouse model: intra-rectal and intra-peritoneal, following which, gut mucosal and systemic antibody responses against ovalbumin (Immunoglobulins G and Immunoglobulins A) were analyzed by Enzyme-Linked Immuno Assay in intestinal contents and in sera. In addition, ovalbumin-specific immunoglobulin producing cells were detected in the intestinal lamina propria by Enzyme-Linked Immunospot. Results showed that FliC as adjuvant for immunization targeting ovalbumin was able to stimulate a gut mucosal and systemic antibody response independently of the immunization route. In order to develop a mucosal vaccine to prevent C. difficile intestinal colonization, we assessed in a mouse model the efficacy of FliC as adjuvant compared with cholera toxin co-administrated with the C. difficile S-layer precursor SlpA as antigen. After challenge, a significant decrease of C. difficile intestinal colonization was observed in immunized groups compared to the control group. Our results showed that C. difficile FliC could be used as adjuvant in mucosal vaccination strategy against C. difficile infections.